FLT3 and acute myeloid leukemia: The clinical response to treatment in our retrospective cohort of patients with acute myeloid leukaemia only partially followed the cytogenetic and molecular risk classification (appendix pp 3, 6), with, for instance, all four patient who had a FLT3-ITD mutation in the non-responders group and both inv(16) patients in the complete remission group.